UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/687,848	10/17/2003	Richard S. Ginn	937.04.01	2084
8685 DERGOSITS &	7590 07/09/201 z <b>NOAH LLP</b>	EXAMINER		
Three Embarcadero Center Suite 410 SAN FRANCISCO, CA 94111			TYSON, MELANIE RUANO	
			ART UNIT	PAPER NUMBER
			MAIL DATE	DELIVERY MODE
			07/09/2010	PAPER

# Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

	Application No.	Applicant(s)				
	10/687,848	GINN, RICHARD S.				
Office Action Summary	Examiner	Art Unit				
	MELANIE TYSON	3773				
The MAILING DATE of this communication app Period for Reply	pears on the cover sheet with the c	orrespondence address				
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.  - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.  - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.  - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).						
Status						
1) Responsive to communication(s) filed on 19 A	pril 2010.					
,	s action is non-final.					
<i>i</i> =	,					
closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.						
Disposition of Claims						
4)⊠ Claim(s) <u>1,3,5,7,9 and 11</u> is/are pending in the application.						
4a) Of the above claim(s) <u>5 and 7</u> is/are withdrawn from consideration.						
5) Claim(s) is/are allowed.						
6)⊠ Claim(s) <u>1,3,9, and 11</u> is/are rejected.						
7) Claim(s) is/are objected to.						
8) Claim(s) are subject to restriction and/c	r election requirement.					
Application Papers						
9)☐ The specification is objected to by the Examiner.						
10) ☐ The drawing(s) filed on is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.						
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).						
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).						
11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.						
Priority under 35 U.S.C. § 119						
12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of:						
1. Certified copies of the priority documents have been received.						
2. Certified copies of the priority documents have been received in Application No						
3. Copies of the certified copies of the priority documents have been received in this National Stage						
application from the International Bureau (PCT Rule 17.2(a)).						
* See the attached detailed Office action for a list of the certified copies not received.						
Au. 1						
Attachment(s)  1) Notice of References Cited (PTO-892)  4) Interview Summary (PTO-413)						
2) Notice of Draftsperson's Patent Drawing Review (PTO-948) Paper No(s)/Mail Date						
3) Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date	5) ☐ Notice of Informal P 6) ☐ Other:	atent Application				

Application/Control Number: 10/687,848 Page 2

Art Unit: 3773

### **DETAILED ACTION**

## Continued Examination Under 37 CFR 1.114

A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 19 April 2010 has been entered. Claims 2, 4, 6, 8, 10, and 12 remain cancelled. Claims 5 and 7 remain withdrawn from consideration. The amendments made to the claims do not place the application in condition for allowance for the reasons set forth below.

# Response to Arguments

Applicant's arguments with respect to claims 1, 3, 9, and 11 have been considered but are most in view of the new ground(s) of rejection.

### Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Claims 1, 3, 9, and 11 are rejected under 35 U.S.C. 102(b) as being anticipated by Kensey (U.S. Patent No. 5,061,274). Kensey discloses a locator device (see entire document) comprising an elongate member (38) having a distal opening in its distal region and a proximal opening in its proximal region which are connected by a

Art Unit: 3773

lumen (for example, see Figure 3), wherein the distal region has a substantially uniform diameter, and a bioabsorbable and expandable occlusion member (20; for example, see column 5, lines 44-45) attached to a specific position on the distal region of the elongate member such that it is in contact with the lumen of the elongate member (at the distal opening) and extends distally of the distal opening of the elongate member (for example, see Figure 3), wherein the occlusion member is capable of substantially blocking blood flow out of the blood vessel at a position outside the blood vessel, and wherein the elongate member is capable of being positioned in a blood vessel such that blood can enter the distal opening without passing through the occlusion member (they are separate components).

#### Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to MELANIE TYSON whose e-mail address is <a href="mailto:melanie.tyson@uspto.gov">melanie.tyson@uspto.gov</a> and telephone number is (571) 272-9062. The examiner can normally be reached on Monday through Thursday 8-7 (max flex).

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Jackie Ho can be reached on (571) 272-4696. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR.

Status information for unpublished applications is available through Private PAIR only.

Application/Control Number: 10/687,848 Page 4

Art Unit: 3773

For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Melanie Tyson /M. T./ Examiner, Art Unit 3773 July 7, 2010